Obinutuzumab in Primary FSGS
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Primary Focal Segmental Glomerulosclerosis (FSGS) Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months. |
Drug: Obinutuzumab
1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
|
Outcome Measures
Primary Outcome Measures
- Change in proteinuria [Baseline, 6 months, 12 months]
Measured using 24 hour urine collection reported in mg/24h
Secondary Outcome Measures
- Remission status at 6 months [6 months]
The number of subjects to reach either complete remission or partial remission at 12 months after infusion. Complete remission defined as proteinuria < 0.3g/24 hrs. and no more than 20% decline in eGFR. Partial remission defined as 50% reduction in proteinuria and proteinuria < 3.5 g/24hrs and no more than 20% decline in eGFR.
- Remission status at 12 months [12 months]
The number of subjects to reach either complete remission or partial remission at 12 months after infusion. Complete remission defined as proteinuria < 0.3g/24 hrs. and no more than 20% decline in eGFR. Partial remission defined as 50% reduction in proteinuria and proteinuria < 3.5 g/24hrs and no more than 20% decline in eGFR.
- Change in serum albumin [Baseline, 6 months, 12 months]
Blood serum collected and reported in g/dL
- Serious Adverse Events (SAEs) [24 months]
Number of subjects to experience serious adverse events including serious infection defined as severe UTI or pyelonephritis, pneumonias or other systemic infections requiring hospitalization
- Proteinuria at 18 months [18 months]
Measured using 24 hour urine collection reported in mg/24h
- Proteinuria at 24 months [24 months]
Measured using 24 hour urine collection reported in mg/24h
Eligibility Criteria
Criteria
Inclusion Criteria:
-
≥ 18 years of age.
-
Biopsy proven Focal Segmental Glomerulosclerosis (FSGS) lesion
-
Foot process effacement ≥ 80% on electron microscopy.
-
Presence of nephrotic syndrome (proteinuria > 3.5g/24hrs and serum albumin < 3.5 g/dl) prior to initiation of immunosuppressive therapy.
-
Resistant or dependent on therapy, including corticosteroids or calcineurin inhibitors or who have failed rituximab. Patient who have contraindication to or refuse to take high dose corticosteroids are allowed.
Exclusion Criteria:
-
Genetic or secondary forms of FSGS.
-
Hepatitis B, C or HIV positive.
-
Pregnant or breast-feeding.
-
Active infection.
-
Kidney transplant.
-
Anemia with Hgb < 8.0 g/dL.
-
Thrombocytopenia with platelet count < 100'000.
-
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication.
-
Patients who have received cyclophosphamide in the last 6 months.
-
Patients who received rituximab previously with CD20 count of < 5 cells/microliter at the time of enrollment.
-
For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug.
-
For men: agreement to remain abstinent or use two adequate methods for contraception, including at least one method with failure rate of less than 1% per year during the treatment period and for at least 6 months (180 days) after the last dose of drug.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
- Genentech, Inc.
Investigators
- Principal Investigator: Fernando Fervenza, MD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 21-003887